Translating Astatine-211 Targeted Alpha Therapy From Preclinical Development to First-in-Human Studies
5:00 pm - Wednesday 24th February 2027
- Translate novel At-211 compounds from discovery through preclinical development, examining the studies required to build confidence ahead of clinical translation
- Navigate preclinical toxicity & translational considerations when progressing an At- 211 program towards FIH evaluation
- Share lessons from investigator-initiated Phase I development to identify what early-stage RLT developers should consider when designing the next generation of alpha-emitting therapeutics
Novel Target
